Trinity Biotech (TRIB) announced the launch of a new testing service for preeclampsia, a significant advancement in maternal health diagnostics. The service is planned to be rolled out in Q3 2025 through Trinity Biotech’s New York-based reference laboratory. Trinity Biotech will offer the FDA-cleared PreClara Ratio biomarker test as part of a strategic collaboration with Thermo Fisher Scientific (TMO), enhancing Trinity Biotech’s capabilities to deliver critical maternal health diagnostics. The sFlt-1/PlGF test provides time-sensitive, clinically actionable insights that support healthcare providers in making earlier, more informed decisions for hospitalized patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Launches CGM+ Platform for AI Wearables Market
- Trinity Biotech unveils CGM+, next-gen wearable biosensor platform
- Trinity Biotech Achieves Profitability Milestone Amid Strategic Turnaround
- Trinity Biotech reports Q1 revenue $7.6M
- Trinity Biotech reaches profitability inflection point, marks major milestone